SDP Oncology Announces First Patient Dosed in a Phase 1 Solid Tumor Study

October 16, 2020

Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently announced that the first patient has been dosed with the PKM2 activator, TP-1454, in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors. 

“Dosing the first patient in this study marks an important milestone, as TP-1454 is the first PKM2 activator to be evaluated in patients with cancer. We look forward to further understanding the safety and efficacy of TP-1454 alone and in combination in patients with solid tumors and applying these learnings to advance the compound,” said Patricia S. Andrews, Chief Executive Officer and Global Head of Oncology, SDP Oncology. 

“This is another significant step forward not only for SDP Oncology, but for patients the world over whose lives are cut short by cancer,” said Kelvyn Cullimore, president and CEO of BioUtah.

This study will assess the safety of oral TP-1454 as monotherapy and as combination therapy with ipilimumab and nivolumab and establish the dose for future studies of TP-1454 as a monotherapy and in combination. Additional information on this trial, including comprehensive inclusion and exclusion criteria, can be accessed at www.ClinicalTrials.gov (NCT04328740).